News

What you experience in your dreams might feel random and disjointed, but that chaos during sleep might serve a function, according to Erin Wamsley, PhD, an associate professor of psychology and neuroscience at Furman University in Greenville, SC. In fact, evidence uncovered by Wamsley and her team suggests that dreams can prepare the mind for
0 Comments
While the investigation into cases of myocarditis possibly associated with COVID vaccines proceeds, the American Heart Association (AHA)/American Stroke Association (ASA) continue to urge everyone who is eligible for the vaccine to get it without delay. “We remain confident that the benefits of vaccination far exceed the very unusual risks,” the leadership of the AHA/ASA
0 Comments
Inpatient care utilization for hidradenitis suppurativa (HS) was higher for Black and Hispanic patients, compared with White patients, in an analysis of the 2019-2019 National Inpatient Sample. The differences occurred despite Black and Hispanic patients being younger at the time of admission than White patients, and may reflect increased disease severity and management challenges in
0 Comments
WASHINGTON — The shortage of school nurses, high prescription drug prices, mask mandates, and youth suicide were among the topics Health and Human Services (HHS) Secretary Xavier Becerra encountered at a House Education and Labor Committee hearing Wednesday on the HHS budget request for fiscal year 2022. “We have a police officer in every school;
0 Comments
The use of artificial intelligence in creating radiation treatment plans for prostate cancer appeared to be a success, according to a blinded, head-to-head study. Overall, radiation oncologists considered the vast majority — 89 of 100 — of machine learning (ML)-generated plans clinically acceptable for treatment, reported Thomas Purdie, PhD, and colleagues at Princess Margaret Cancer
0 Comments
Patients hospitalized with COVID-19 pneumonia who were treated with tofacitinib (Xeljanz) had a significantly lower incidence of death or respiratory failure than those treated with placebo, a randomized trial in Brazil found. Cumulative incidence of death or respiratory failure through day 28 was significantly lower in the tofacitinib group than in controls (18.1% vs 29.0%,
0 Comments
Patients hospitalized with COVID-19 pneumonia who were treated with tofacitinib (Xeljanz) had a significantly lower incidence of death or respiratory failure than those treated with placebo, a randomized trial in Brazil found. Cumulative incidence of death or respiratory failure through day 28 was significantly lower in the tofacitinib group than in controls (18.1% vs 29.0%,
0 Comments
Comatose out-of-hospital cardiac arrest (OHCA) survivors fared no better on targeted temperature management (TTM) than standard care for avoiding fever in the ICU, according to the TTM2 trial. There was no significant difference between the 50% incidence of all-cause death at 6 months among patients randomized to targeted hypothermia at 33°C (91.4°F) and the 48%
0 Comments